Aeromics has begun a Phase l clinical trial of AER-271 to treat severe ischemic stroke.

The double-blind, randomised, placebo-controlled trial intends to investigate the pharmacokinetics, safety and tolerability of AER-271 in single-ascending and multiple-ascending doses of AER-271.

As part of the trial, AER-271 will be administered intravenously (IV) to a total of 78 healthy subjects at Covance’s cGMP facility in Dallas, Texas.

Aeromics had already dosed the first cohort last month and expects to complete the trial by May next year.

Results from the trial will be used to outline the design of a proposed, potentially pivotal, multi-centre Phase ll efficacy study of AER-271 in severe ischemic stroke patients with Large Hemispheric Infarction (LHI).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The initiation of our Phase l study represents the first Aquaporin inhibitor to enter first-in-human trials.”

Aeromics president and CEO Dr Marc Pelletier said: “The initiation of our Phase l study represents the first Aquaporin inhibitor to enter first-in-human trials.

“Our team is excited about AER-271 and it’s application to edema control in severe stroke. AER-271 could offer a critical step forward in treatment options for physicians.

“Due to the late onset of edema, this new therapy would significantly extend the time-to-treatment window over the standard of care tPA. Many more patients will benefit than is currently possible.”

AER-271 is an investigational IV prodrug that is designed to provide AER-270, a potent inhibitor of Aquaporin-4 (AQP4) water channels, to the neurovascular unit.

The AQP4 channels are the main route used to move water into the central nervous system under conditions of ischemia.